Hepatitis B and C: Management and Treatment, Second Edition

Book Cover......Page 1
Title......Page 3
Copyright......Page 4
Contents......Page 5
Introduction......Page 8
I Hepatitis C......Page 10
1. Natural History of Hepatitis C: Epidemiology......Page 11
2. Natural History of Hepatitis C: Hepatic Manifestations......Page 14
3. Natural of Hepatitis C: Extrahepatic Manifestations and Quality of Life......Page 23
4. Management Protocols in Chronic Hepatitis C......Page 27
5. Management of Relapsers and Nonresponders—Maintenance Therapy......Page 46
6. Management of Patients with Cirrhosis......Page 50
7. Management of Patients Coinfected by HCV and HIV......Page 54
8. Management of HCV Infection After Liver Transplantation......Page 56
9. Management of Patients with Renal Disease......Page 58
10. Other Difficult-to-treat Populations......Page 59
11. Safety of Interferon, Pegylated Interferon (PEG-IFN) and Ribavirin......Page 61
12. Who Needs to be Treated and How to Explain the Goals to the Patient......Page 67
13. What is the Cost-effectiveness of Combination Regiments?......Page 69
14. Management of Acute Hepatitis C......Page 72
15. Practical Guidelines for the Management of Hepatitis C......Page 74
16. New Drugs in Development......Page 77
References......Page 81
II Hepatitis B......Page 88
17. Natural History of Hepatitis B: Epidemiology......Page 89
18. Natural History of Hepatitis B: Hepatic Manifestations......Page 93
19. Natural History of Hepatitis B: Extrahepatic Manifestations and Quality of Life......Page 102
20. Goal of Treatment in Chronic Hepatitis B......Page 105
21. Efficacy of Interferon and Pegylated Interferon (PEG-IFN)......Page 107
22. Efficacy of Lamivudine......Page 111
23. Comparison Between Lamivudine, Interferon and the Combination of Interferon and Lamivudine......Page 118
24. Safety of Lamivudine......Page 120
25. Efficacy of Adefovir......Page 121
26. Safety of Adefovir......Page 124
27. First-line Treatment of Chronic Hepatitis B: Adefovir, Lamivudine or Interferon?......Page 126
28. New Drugs in Development......Page 127
29. Who Needs to be Treated and How to Explain the Goals to the Patient......Page 128
30. Management of Relapsers and Nonresponders......Page 131
31. Management of Patients Coinfected by HBV and HIV......Page 132
32. Management of Transplanted Patients Chronically Infected by HBV......Page 133
33. Cost-effectiveness of Treatment......Page 134
References......Page 135
III Biochemical Markers: An Alternative to Liver Biopsies......Page 141
34. Needle Biopsy of the Liver: Value and Limitations......Page 142
35. Advantage and Limits of Biochemical Markers......Page 151
References......Page 158